Novocure gets FDA approval for its HFE transducer arrays for glioblastoma treatment

seekingalpha11-21 22:05

Anna Bliokh/iStock via Getty Images Novocure (NASDAQ:NVCR) announced that the U.S. FDA approved its new Head Flexible Electrode transducer arrays for use with Optune Gio for the treatment of adult ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2485049443?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1326499418/image_1326499418.jpg","is_english":true,"pubTime":"2024-11-21 22:05","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2485049443","market":"sh","top_or_hot":-1,"title":"Novocure gets FDA approval for its HFE transducer arrays for glioblastoma treatment","media":"seekingalpha","content":"<div>\n<p>Anna Bliokh/iStock via Getty Images  Novocure (NASDAQ:NVCR) announced that the U.S. FDA approved its new Head Flexible Electrode transducer arrays for use with Optune Gio for the treatment of adult ...</p>\n\n<a href=\"https://seekingalpha.com/news/4316776-novocure-gets-fda-approval-for-its-hfe-transducer-arrays-for-glioblastoma-treatment\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novocure gets FDA approval for its HFE transducer arrays for glioblastoma treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovocure gets FDA approval for its HFE transducer arrays for glioblastoma treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-21 22:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4316776-novocure-gets-fda-approval-for-its-hfe-transducer-arrays-for-glioblastoma-treatment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Anna Bliokh/iStock via Getty Images  Novocure (NASDAQ:NVCR) announced that the U.S. FDA approved its new Head Flexible Electrode transducer arrays for use with Optune Gio for the treatment of adult ...</p>\n\n<a href=\"https://seekingalpha.com/news/4316776-novocure-gets-fda-approval-for-its-hfe-transducer-arrays-for-glioblastoma-treatment\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVCR","symbol_name":"NovoCure Limited","start_time":0,"source_url":"https://seekingalpha.com/news/4316776-novocure-gets-fda-approval-for-its-hfe-transducer-arrays-for-glioblastoma-treatment","article_id":"2485049443","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1326499418/image_1326499418.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485049443","pubTimestamp":1732197943,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Anna Bliokh/iStock via Getty Images  Novocure  announced that the U.S. FDA approved its new Head Flexible Electrode transducer arrays for use with Optune Gio for the treatment of adult patients with glioblastoma multiforme. Optune Gio is a wearable, portable device that produces alternating electric fields known as Tumor Treating Fields, which are delivered through non-invasive, wearable arrays.  Novocure plans to convert Optune Gio users in the U.S. to the new HFE arrays through the first half of 2025 through a controlled transition plan. Source: Press Release","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVCR":"NovoCure Limited","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","BK4588":"碎股","BK4548":"巴美列捷福持仓","BK4082":"医疗保健设备"},"translate_title":"Novocure的HFE传感器阵列用于胶质母细胞瘤治疗获得FDA批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVCR":0.9},"content_text":"Anna Bliokh/iStock via Getty Images  Novocure (NASDAQ:NVCR) announced that the U.S. FDA approved its new Head Flexible Electrode transducer arrays for use with Optune Gio for the treatment of adult patients with glioblastoma multiforme. Optune Gio is a wearable, portable device that produces alternating electric fields known as Tumor Treating Fields, which are delivered through non-invasive, wearable arrays.  Novocure plans to convert Optune Gio users in the U.S. to the new HFE arrays through the first half of 2025 through a controlled transition plan. Source: Press Release","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2485049443"}